TABLE 2.
Characteristics of included studies.
| Id | Mean age (mean ± SD) | Total/male/female | Population | LOS (day) | Dosage (g/d) | Administration route | Frequency | Control (n) | O3FA (n) | Parameter | Staging |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhang et al. (2020) | T:NA | T:90/47/43 | chemotherapy | 30 | EPA:0.064 | PO | tid | 89 | 90 | ⑨ | TNM: III, Ⅳ |
| C:NA | C:89/46/43 | ||||||||||
| Haidari et al. (2020a) | T:56.75 ± 10.60 | T:20/12/8 | chemotherapy + surgery | 56 | EPA:0.108 | PO | qd | 20 | 20 | ⑤⑥⑩ | TNM: II, III |
| C:59.90 ± 8.75 | C:20/8/12 | ||||||||||
| Haidari et al. (2020b) | T:56.75 ± 10.60 | T:20/12/8 | chemotherapy + surgery | 57 | EPA:0.108 | PO | qd | 20 | 20 | ①②③⑤⑩⑪ | TNM: II, III |
| C:59.90 ± 8.76 | C:20/8/12 | ||||||||||
| Bakker et al. (2020a) | T: 65 [64,72] | T:17/12/5 | surgery | 2 | EPA:0.135 | PN | qd | 18 | 17 | ③⑤⑦⑧ | TNM:I, II, III |
| C: 68 [63,73] | C:18/12/6 | ||||||||||
| Marianne Schoorla 2020 | T:65.00 (12.00) | T:18/13/5 | surgery | 2 | EPA:0.163 | PN | qd | 23 | 18 | ⑦ | TNM:I, II, III |
| C:69.00 (11.00) | C:23/15/8 | ||||||||||
| Hossain et al. (2020) | T: 69.03 (7.95) | T:32/24/8 | surgery | 26 | EPA:1.000 | PO | tid | 29 | 32 | ⑦⑧ | Duke:A, B, C |
| C: 67.42 (6.92) | C:29/18/11 | ||||||||||
| Sørensen et al. (2020) | T: 68.30 (11.30) | T:65/27/38 | surgery | 14 | EPA:2.000 | PO | bid | 60 | 65 | ④⑦⑧ | UICC:I, II, III, Ⅳ |
| C: 70.60 (10.10) | C:60/30/30 | ||||||||||
| Golkhalkhali et al. (2018) | T:NA | T:70 | chemotherapy + surgery | 56 | EPA:0.700 | PO | qd | 70 | 70 | ②③⑤⑨⑩⑪ | NA |
| C:NA | C:70 | ||||||||||
| Ma et al. (2015) | T: 61.55 ± 9.78 | T:51/29/22 | surgery | 8 | EPA:0.900 | TPN | qd | 48 | 51 | ②③⑤⑦⑩ | UICC:I, II, III, Ⅳ |
| C:62.85 ± 10.12 | C:48/27/21 | ||||||||||
| Sorensen et al. (2014a) | T: 69.00 (11.00) | T:74/44/30 | surgery | 14 | EPA:2.000 | PO | bid | 74 | 74 | ④⑦⑧ | TNM:I, II, III, Ⅳ |
| C: 71.00 (10.00) | C:74/36/38 | ||||||||||
| Sorensen et al. (2014b) | T: 69.00 (11.00) | T:74/44/30 | surgery | 7 | EPA:2.000 | PO | bid | 74 | 74 | ④ | TNM:I, II, III, Ⅳ |
| C: 71.00 (10.00) | C:74/36/38 | ||||||||||
| Cockbain et al. (2014) | T: 68 (44–82) | T:43/26/17 | chemotherapy + surgery | 30 (12–65) | EPA:0.600 | PO | bid | 45 | 43 | ④⑦ | Duke:A, B, C, D |
| C: 71 (35–87) | C:45/35/10 | ||||||||||
| Mocellin et al. (2013) | T: 55.20 (7.70) | T:6/3/3 | chemotherapy + surgery | 63 | EPA:0.360 | PO | qd | 5 | 6 | ①②③⑥⑩⑪ | TNM:III, Ⅳ |
| C: 53.60 (12.90) | C:5/3/2 | ||||||||||
| Zhu et al. (2012) | T: 69.80 ± 10.50 | T:29/16/13 | surgery | 7 | EPA:0.600 | TPN | qd | 28 | 29 | ⑤⑦⑧⑩ | Duke:B, C |
| C: 70.80 ± 6.40 | C:28/17/11 | ||||||||||
| Silva etal. (2012) | T: 50.10 (8.20) | T:11/3/8 | chemotherapy + surgery | 63 | EPA:0.180 | PO | qd | 12 | 11 | ①②③⑤⑥⑩⑪ | TNM:I, II, III, Ⅳ |
| C: 54.30 (9.30) | C:12/3/9 | ||||||||||
| Chen et al. (2011) | T: NA | T:102/49/53 | surgery | NA | EPA:0.180 | TPN | NA | 65 | 102 | ④⑦⑧ | NA |
| C: NA | C:65 | ||||||||||
| Trabal et al. (2010) | T: 61.50 ± 15.80 | T:6/4/2 | chemotherapy | 84x | EPA:1.600 | PO | NA | 7 | 6 | ⑦⑨⑪ | TNM: Ⅳ |
| C: 68.20 ± 15.60 | C:7/5/2 | ||||||||||
| Liang et al. (2008) | T: 55.80 ± 10.10 | T:20/10/10 | surgery | 7 | EPA:0.600 | TPN | qd | 21 | 20 | ⑤⑦⑧⑩ | TNM:I, II, III |
| C: 59.19 ± 10.61 | C:21/15/6 | ||||||||||
| Braga et al. (2002) | T: 60.50 ± 11.50 | T:50/28/22 | surgery | T:9.80 ± 3.10 C:12.2 ± 3.90 | EPA:1.152 | EN | qd | 50 | 50 | ④⑦⑧ | NA |
| C: 62.20 ± 10.40 | C:50/29/21 |
①Albumin; ②BMI; ③C-reactive protein (CRP); ④CRC, mortality; ⑤IL-6 (interleukin-6); ⑥IL-1β; ⑦rates of infectious and non-infectious complications; ⑧Length of hospital stay (LOS); ⑨Quality of life; ⑩Tumor necrosis factor-α (TNF-α); ⑪Weight. LOS, length of hospital stay; O3FA, omega-3 polyunsaturated fatty acids; NA, not available; T, treatment; C, control; PO, per oral; PN, parenteral nutrition; TPN, total parenteral nutrition; EN, enteral nutritiopn.